Evidence map›Paper›PMID 41493663›Full record

ArticleFamilial cancer2026

Beyond 1100delC: distinct CHEK2 variants and unique cancer phenotypes in Northeast Brazil.

Mariana Macambira Noronha, Pedro Robson Costa Passos, Valbert Oliveira Costa Filho, Thais Baccili Cury Megid, Fernanda Teresa de Lima, Danielle Calheiros Campelo Maia

Abstract read
PubMed Publisher
In one paragraph

Article in Familial cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mariana Macambira NoronhaDepartment of Medical Sciences, Universidade Federal do Ceará, St. Alexandre Baraúna, 949, Rodolfo Teófilo, Fortaleza, CE, 60430-160, Brazil. mariananoronha@alu.ufc.br.
Pedro Robson Costa PassosDepartment of Medical Sciences, Universidade Federal do Ceará, St. Alexandre Baraúna, 949, Rodolfo Teófilo, Fortaleza, CE, 60430-160, Brazil.
Valbert Oliveira Costa FilhoDepartment of Medical Sciences, Universidade Federal do Ceará, St. Alexandre Baraúna, 949, Rodolfo Teófilo, Fortaleza, CE, 60430-160, Brazil.
Thais Baccili Cury MegidDivision of Medical Oncology, Dr. Georges-L.-Dumont University Hospital Centre, Moncton, Canada.
Fernanda Teresa de LimaCenter for Precision Medicine, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Danielle Calheiros Campelo MaiaDepartment of Medical Oncology, Hospital Universitário Walter Cantídeo, Fortaleza, CE, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The CHEK2 gene confers a moderate risk for breast cancer, but existing knowledge is largely based on the European founder variant, 1100delC. This study aimed to characterize the distinct phenotypes associated with unique CHEK2 variants in Brazilian families. In this cross-sectional study, 1055 patients meeting criteria for Hereditary Breast and Ovarian Cancer syndrome underwent germline multigene panel testing. Pathogenic/likely pathogenic variants (PVs) were found in 141 patients (13.4%), of whom 13 (9.2%) had a CHEK2 PVs. Subsequent family cascade testing brought the total number of individuals studied to 57. Three distinct CHEK2 PVs were identified: c.846 + 1G > C, c.349 A > G, and c.593-1G > T. While breast cancer was the most frequent tumor, specific PVs correlated with different cancer spectra. The c.349 A > G variant showed an enrichment for papillary thyroid cancer. In contrast, the c.846 + 1G > C variant was associated with melanoma, prostate, and testicular cancer, in addition to breast, colon, and kidney cancers. These findings suggest that different CHEK2 PVs may confer distinct cancer risks. Investigating these variants across diverse populations is crucial for refining phenotype characterization and improving genetic counseling as access to genetic testing expands.

Indexed as

Checkpoint Kinase 2Hereditary Breast and Ovarian Cancer SyndromeNeoplasmsAdultAgedBrazilCross-Sectional StudiesFemaleGenetic Predisposition to DiseaseGenetic TestingGerm-Line MutationHumansMaleMiddle AgedPhenotypeYoung AdultCheckpoint Kinase 2CHEK2 protein, humanBrazilCHEK2Phenotype

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.